After winning hearts with his performance in the 2019 blockbuster Kesari, Akshay Kumar has returned with the second ...

A division bench of Justices M S Sonak and Jitendra Jain remarked that the facility to seek urgent hearing cannot be invoked ...

As of the first nine months of FY25, 94% of Tejas Network's revenue came from India, primarily driven by BSNL’s 4G-related ...

The government has amended the Government Savings Promotion General Rules, 2018, through a Gazette notification issued on ...

In the past, Trump suggested a 10% tax on all imports. However, he has also talked about increasing tariffs to 20% or even 60 ...

Jaimini Bhagwati, Distinguished Fellow, Centre for Social and Economic Progress (CSEP) believes that lowering duties could ...

X further accused the Indian government of engaging in “mudslinging” against the company. However, India maintains that all ...

IDBI Bank reported a 13% year-on-year (YoY) increase in total business for Q4 FY25, reaching ₹5,28,714 crore compared to ₹4,66,278 crore in Q4 FY24. The bank's total deposits stood at ₹3,10,293 crore, ...

Marico's India business posted a sequential uptick in underlying volume growth, while the international business delivered ...

The non-banking financial company (NBFC) announced that its Assets Under Management (AUM) grew by 42.2% year-on-year (YoY) and 14.7% quarter-on-quarter (QoQ), reaching approximately ₹35,550 crore as ...

Other names on the Nifty Pharma index that has a significant upside potential include Aurobindo Pharma and Ajanta Pharma, both of which have an upside potential of 23%.

The lender's global advances increased by 12.88% to ₹12.3 lakh crore from ₹10.9 lakh crore in the previous year.